This site is intended for U.S. healthcare professionals.
Voranigo® (vorasidenib) tablets logo
Connect with a rep ›
Voranigo® (vorasidenib) tablets logo

Is VORANIGO® appropriate for your patients?

Learn what types of patients with mIDH glioma may be appropriate for VORANIGO after surgery1

Hypothetical patient Grace.

GRACE

  • Grade 2 oligodendroglioma

  • Gross total resection 3 months ago

Expand
Collapse
Hypothetical patient Randy.

RANDY

  • Grade 2 astrocytoma

  • Tumor recurrence 1.5 years after gross total resection

Expand
Collapse
Hypothetical patient Stacie.

STACIE

  • Grade 2 astrocytoma

  • Sub-total resection 3 months ago

Expand
Collapse
Hypothetical patient Steven.

STEVEN

  • Grade 2 oligodendroglioma

  • Sub-total resection 4.5 years ago

Expand
Collapse
Hypothetical patient Ryan.

RYAN

  • Grade 2 astrocytoma

  • Tumor progression post-RT/CT

Expand
Collapse

Hypothetical patients.

Hypothetical patient Grace.

GRACE

  • Grade 2 oligodendroglioma
  • Gross total resection 3 months ago
Expand
Hypothetical patient Grace.

MEET GRACE

Grace has Grade 2 oligodendroglioma and received a gross total resection 3 months ago

VORASIDENIB IS

NCCN

PREFERRED

Vorasidenib (VORANIGO) is an NCCN preferred treatment option for patients like Grace2

Learn more

Patient Information

  • Age: 26
  • Occupation: Interior designer
  • Support system includes: Louise and John (parents) and Andrew (fiancé)
  • Hobbies: Dancing and traveling

Clinical Summary

  • Diagnosis: Grade 2 oligodendroglioma
  • Time after surgery: 3 months
  • Surgical result: Gross total resection
  • Additional consultation: Recently met with an onco-fertility specialist to discuss family planning options

Clinical History

  • Presentation: Occasional dizziness, mild headache; got a CT scan after a fall that identified a tumor
  • Mutation profile: IDH1 R132H mutation and 1p/19q-codeletion
  • Pre-surgical tumor size: ~3.3 cm diameter
  • Relevant labs: Normal BMP, LFTs, and CBC
  • Relevant MRI scans: No evidence of residual disease at 3-month post-op scan
  • Performance evaluation (KPS score): 90

Hypothetical patient.

Collapse
Hypothetical patient Randy.

RANDY

  • Grade 2 astrocytoma
  • Tumor recurrence 1.5 years after gross total resection
Expand
Hypothetical patient Randy.

MEET RANDY

Randy has Grade 2 astrocystoma and has residual/measurable disease after surgery, which recurred approximately 1.5 years after his gross total resection

VORASIDENIB IS

NCCN

PREFERRED

Vorasidenib (VORANIGO) is an NCCN Category 1 preferred treatment option for patients like Randy2

Learn more

Patient Information

  • Age: 36
  • Occupation: Retail purchasing and stocking
  • Support system includes: Alicia (wife) and Garrett (brother)
  • Hobbies: Sports and outdoor activities

Clinical Summary

  • Diagnosis: Grade 2 astrocytoma
  • Time after surgery: 1.5 years
  • Surgical result: Gross total resection
  • Most recent status: MRI scan indicates tumor recurrence

Clinical History

  • Presentation: 6 months of increasing headaches and blurry vision
  • Mutation profile: IDH1 R132H mutation, CDKN2A/B intact
  • Pre-surgical tumor size: 3 x 5 cm
  • Follow-up history: No residual disease immediately following surgery, follow-up scans showed no sign of recurrence until most recent scan
  • Relevant labs: Normal LFTs; Creatinine 1.3 mg/dL
  • Performance evaluation (KPS score): 100

Hypothetical patient.

Collapse
Hypothetical patient Stacie.

STACIE

  • Grade 2 astrocytoma
  • Sub-total resection 3 months ago
Expand
Hypothetical patient Stacie.

MEET STACIE

Stacie has Grade 2 astrocytoma and received a sub-total resection 3 months ago

VORASIDENIB IS

NCCN

PREFERRED

Vorasidenib (VORANIGO) is an NCCN Category 1 preferred treatment option for patients like Stacie2

Learn more

Patient Information

  • Age: 39
  • Occupation: Full-time worker at a childcare center and part-time student
  • Support system includes: Samantha (sister) and Candice (best friend)
  • Hobbies: Writing and running

Clinical Summary

  • Diagnosis: Grade 2 astrocytoma
  • Time after surgery: 3 months
  • Mutation profile: Sub-total resection

Clinical History

  • Presentation: Seizures, worsening headaches, experienced episodes of numbness/tingling in left side of face lasting for minutes, leading to brain imaging
  • Mutation profile: IDH1 R132H mutation and CDKN2A/B intact
  • Pre-surgical tumor size: 3.6 x 2.7 cm
  • Post-surgical tumor size: 2.5 x 2.0 cm
  • Relevant labs: Normal BMP, LFTs, and CBC
  • Relevant MRI scans: 3-month post-op MRI shows 2.5 cm residual tumor, mild post-surgical edema and no enhancement
  • Performance evaluation (KPS score): 80

Hypothetical patient.

Collapse
Hypothetical patient Steven.

STEVEN

  • Grade 2 oligodendroglioma
  • Sub-total resection 4.5 years ago
Expand
Hypothetical patient Steven.

MEET STEVEN

Steven has Grade 2 oligodendroglioma and continues to have residual/measurable disease after a sub-total resection multiple years ago

VORASIDENIB IS

NCCN

PREFERRED

Vorasidenib (VORANIGO) is an NCCN Category 1 preferred treatment option for patients like Steven2

Learn more

Patient Information

  • Age: 61
  • Occupation: Farmer
  • Support system includes: Sharon (wife), Lily (daughter), and Sam (son)
  • Hobbies: Fishing and beekeeping

Clinical Summary

  • Diagnosis: Grade 2 oligodendroglioma
  • Time after surgery: 4.5 years post-resection with stable residual disease
  • Surgical result: Sub-total resection

Clinical History

  • Presentation: Seizures
  • Mutation profile: IDH1 R132H mutation and 1p/19q-codeletion; CDKN2A/B intact
  • Pre-surgical tumor size: ~5 cm diameter
  • Post-surgical tumor size: 3 cm diameter
  • Relevant labs: Normal BMP, CBC, and bilirubin; ALT 2x ULN
  • Relevant MRI scans: Most recent MRI imaging continues to show stable tumor size
  • Performance evaluation (KPS score): 80

Hypothetical patient.

Collapse
Hypothetical patient Ryan.

RYAN

  • Grade 2 astrocytoma
  • Tumor progression post-RT/CT
Expand
Hypothetical patient Ryan.

MEET RYAN

Ryan has a Grade 2 astrocytoma. 3 years after a sub-total resection followed by chemotherapy/radiation, his tumor is showing signs of progression

VORASIDENIB IS

NCCN

PREFERRED

Vorasidenib (VORANIGO) is an NCCN preferred treatment option for patients like Ryan2

Learn more

Patient Information

  • Age: 45
  • Occupation: Teacher
  • Support system includes: Chris (partner) and colleagues
  • Hobbies: Photography and cooking

Clinical Summary

  • Diagnosis: Grade 2 astrocytoma
  • Time after surgery: 3 years
  • Surgical result: Sub-total resection
  • Most recent status: MRI scans indicate tumor progression

Clinical History

  • Presentation: Minor cognitive deficits (confusion, difficulty concentrating, memory loss)
  • Mutation profile: IDH1 R132H mutation and CDKN2A/B intact
  • Pre-surgical tumor size: 4 x 3.5 cm
  • Post-surgical treatment: 6 weeks of RT, 6 months of adjuvant temozolomide
  • Follow-up history: Stable post-treatment with RT/chemotherapy, continued stability until most recent scan
  • Relevant labs: Normal LFT, normal CBC, creatinine 0.9 mg/dL
  • Performance evaluation (KPS score): 80

Hypothetical patient.

Collapse

Hypothetical patients.

Explore data from the INDIGO trial to see how VORANIGO can help your patients
Learn more

Watch neuro-oncologists discuss real patient cases and why they prescribed VORANIGO

See expert testimonies
Learn about the INDIGO trial for VORANIGO

ALT, alanine transaminase; BMP, basic metabolic panel; CBC, complete blood count; CT, chemotherapy; KPS, Karnofsky Performance Status; LFTs, liver function tests; mIDH, mutant isocitrate dehydrogenase; MRI, magnetic resonance imaging; NCCN, National Comprehensive Cancer Network® (NCCN®); RT, radiotherapy; ULN, upper limit of normal.

References: 1. Voranigo. Package insert. Servier Pharmaceuticals LLC; 2025. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.2.2025. ® National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 12, 2025. To view the most recent and complete version of the guideline, go to NCCN.org NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

caret caret

IMPORTANT SAFETY INFORMATION

INDICATION

VORANIGO (40 mg tablets) is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hepatotoxicity: VORANIGO can cause hepatic transaminase elevations, which can lead to hepatic failure, hepatic necrosis, and autoimmune hepatitis. Monitor liver laboratory tests (AST, ALT, GGT, total bilirubin, and alkaline phosphatase) prior to the start of VORANIGO, every 2 weeks during the first 2 months of treatment, then monthly for the first 2 years of treatment, and as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Reduce the dose, withhold, or permanently discontinue VORANIGO based on severity.

Embryo-Fetal Toxicity: Based on findings from animal studies, VORANIGO can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective nonhormonal contraception during treatment with VORANIGO and for 3 months after the last dose, since VORANIGO can render some hormonal contraceptives ineffective. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VORANIGO and for 3 months after the last dose.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions included fatigue, headache, COVID-19, musculoskeletal pain, diarrhea, nausea, and seizure. Grade 3 or 4 (≥2%) laboratory abnormalities were ALT increased, AST increased, GGT increased, and neutrophils decreased.

DRUG INTERACTIONS

Avoid concomitant use of VORANIGO with strong and moderate CYP1A2 inhibitors. Avoid concomitant use with moderate CYP1A2 inducers and smoking tobacco. Avoid concomitant use with CYP3A substrates, where a minimal concentration change can reduce efficacy. If concomitant use of hormonal contraception cannot be avoided, use nonhormonal contraception methods.

LACTATION

Advise women not to breastfeed during VORANIGO treatment and for 2 months after the last dose.

IMPAIRED FERTILITY

VORANIGO may impair fertility of females and males of reproductive potential.

Please see Full Prescribing Information.

This site uses cookies, and your privacy choice is important to us.

We use cookies to improve your experience, produce audience statistics, offer you services tailored to your interests, and provide features associated with social media. You can change your preferences at any time on the site.

Accept all cookies